Exploratory analysis shows eplontersen improves quality of life in patients with ATTRv-PN, indicating effectiveness across sexes.
Eplontersen halted neuropathy impairment and improved quality of life versus placebo to a similar degree in both male and female patients with ATTRv-PN, including those with cardiomyopathy. These findings support the use of eplontersen as an effective treatment for ATTRv-PN regardless of sex.
No takes yet. Share an insight, caveat, or question.
Waddington‐Cruz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: